Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme

– Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need HOUSTON, Sept. 6, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation of WP1122 for the treatment of Glioblastoma Multiforme (“GBM”).

The release as fetched from its publisher. moleculin.com ↗